Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Bioenvision

1996 FOUNDED
M&A STATUS
31-40 EMPLOYEES
M&A LATEST DEAL TYPE
4 FINANCING ROUNDS
Description

Developer of compounds and technologies for the treatment of cancer.

Formerly Known As
Ascot Group
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 345 Park Avenue
  • 41st Floor
  • New York, NY 10154
  • United States

+1 (212) 000-0000

Bioenvision Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Bioenvision‘s full profile, request access.

Request full access to PitchBook

Bioenvision Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Bioenvision‘s full profile, request access.

Request full access to PitchBook

Bioenvision Executive Team (3)

Name Title Board
Seat
Contact
Info
James Scibetta Chief Financial Officer

2 Former Executives

You’re viewing 1 of 3 executives. Get the full list »